期刊文献+

人载脂蛋白C3基因转基因小鼠的建立及血脂变化分析 被引量:2

Establishment of a Human APOC3 Transgenic Mouse Model and Analysis of the Blood Lipids
下载PDF
导出
摘要 目的制备系统性表达人载脂蛋白C3(APOC3)基因的转基因小鼠,建立高血脂小鼠模型。方法将人APOC3基因插入系统性表达启动子下游,构建转基因表达载体,通过显微注射法建立人APOC3转基因C57BL/6J小鼠。并利用特异引物PCR法鉴定转基因小鼠的基因型,Western blot检测基因表达水平,血生化分析检测不同月龄转基因小鼠与同龄野生型小鼠的血脂指标,脂肪染色观察肝脏脂肪水平。结果建立了高表达人APOC3基因的转基因小鼠品系;转入的人APOC3基因在血液、肝脏、小肠、肌肉、心脏、肾脏、脾脏中均有明显表达;不同月龄转基因小鼠的血浆甘油三酯水平明显高于同龄野生型小鼠;转基因小鼠的肝脏脂肪含量高于野生型小鼠。结论系统性表达人APOC3基因的转基因小鼠表现高脂血症表型,可以作为高血脂以及高血脂相关的心血管病的工具动物。 Objective To generate transgenic mice expressing human APOC3,and establish a mouse model of hyperlipidemia.Methods The transgenic plasmid was constructed by inserting human APOC3 gene into the downstream of the human ubiquitin C(Ubc) promoter.The transgenic mice were produced by microinjection and the genotyping was detected by PCR.The expression level of the gene was determined by Western blotting.The levels of blood lipids of the mice at different ages were detected using a biochemical analyzer.Fat in the liver tissue was observed by histology with fat staining.Results The transgenic mouse model with overexpression of human APOC3 gene was established,showing overexpression of human APOC3 gene in the blood,liver,intestine,muscle,heart,kidney and spleen tissues,compared with those of the wild type mice.The plasma triglyceride phosphate(TG) level and liver fat content of the transgenic mice were significantly higher than those in the wild type mice.Conclusions A transgenic mouse model overexpressing human APOC3 gene and phenotypes of hyperlipidemia has been developed,providing a useful animal model for hyperlipidemia and related angiocardiopathy studies.
出处 《中国比较医学杂志》 CAS 2012年第10期1-5,共5页 Chinese Journal of Comparative Medicine
基金 国家"重大新药创制"科技重大专项课题"啮齿类研发平台创新药物研究开发技术平台建设"(课题编号2011ZX09307-302)
关键词 载脂蛋白C3 转基因小鼠 甘油三酯 高脂血症 人APOC3基因 Apolipoprotein C3 Transgenic mice Triglyceride Hyperlipidemia Human APOC3 gene
  • 相关文献

参考文献15

  • 1Brown S, Ordovas JM, Campos H. Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins [ J ]. Atheresclerosis, 2003, 170 (2) : 307 -313.
  • 2Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipopretein metabolism: functional differences between ApoC1, ApoC2, and ApoC3 [ J]. Arterioscler Thremb Vasc Biol, 1999, 19(3) : 472 -484.
  • 3Teramoto T. Structure and function of apolipoproteins [ J ]. Nippon Rinsho. 1994, 52(12) : 3100 -3107.
  • 4Snieder H, van Doornen LJ, Boomsma DI, et al. The age dependency of gene expression for plasma lipids, lipoproteins, and apolipopreteins [ J ]. Am J Human Genet, 1997, 60 (3) : 13.
  • 5Blankenhorn DH, Alaupovie P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortoeorenary bypass grafts. Lipid and nonlipid factors [ J ]. Circulation, 1990, 80 : 470 - 476.
  • 6Hodis HN, Mack WJ, Azen SP, et al. Triglyeeride and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin [ J ]. Circulation, 1994, 90:42-49.
  • 7Mack WJ, Krauss RM, Hodis HN. Lipopretein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression [ J ]. Arterioscler Thromb Vasc Biol, 1996, 16 : 697 - 704.
  • 8Luc, G, Fievet C, Arveiler D, et al. Apolipoproteins C-Ill and E in apoB and non-apoB-containing lipoprotein in two populations at contrasting risk for myocardial infarction. The ECTIM study[ J]. J Lipid Res, 1996, 37:508 -517.
  • 9Thompson GR. Angiographic evidence for role of triglyceride lipoproteins in progression of coronary artery disease [ J ]. Eur Heart J, 1998, 19:H31-H36.
  • 10Sacks FM, Alaupovic P, Moye LA, ct al. VLDL, apolipoprotcins B, Clll, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial[ J. Circulation, 2000, 102 : 186 - 1892.

二级参考文献53

  • 1王宗保,万腊香,吴端生,吴孟津,杨永宗.人SR-AI转基因小鼠模型的主要形态学特性、血液学指标和血脂水平的研究[J].中国实验动物学报,2001,9(4):201-204. 被引量:6
  • 2庄一义.LCAT、CETP、LpAl在胆固醇逆向转运中的作用[J].上海医学,1997,20(2):121-124. 被引量:7
  • 3Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells[ J]. Cell, 1992,71:343 - 353.
  • 4Nakashima Y,Plump AS, Raines EW, et al. ApoE-deficient mice develop lesions of all phase of atherosclerosis throughout the arterial tree[ J]. Arterioscler Thromb, 1994,14 : 133 - 140.
  • 5Hofker MH, van Vlijmen B J, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis [ J ].Atherosclerosis, 137 : 1 - 11.
  • 6Xiong WJ,Zsigmond E, Gotto AM Jr, et al. Locating a low density lipoprotein targeting domain of human apolipoprotein B-100 by expressing a minigene construct in transgenic mlce[J]. J Biol Chem, 1991,266 : 20893 - 20898.
  • 7Xiong WJ, Zsigmond E, Gotto AMJr, et al. Transgenic mice expressing fuU-length human apolipoprotein B-IO0. Full- lengthhuman apolipoprotein B mRNA is essentially not edited in mouse intestine or liver[J]. J Biol Chem, 1992,267:21412- 21420.
  • 8Chiesa G, Johnson DF, Yao Z, et al. Expression of human apolipoprotein B100 in transgenic mice. Editing of human apolipoprotein B100 mRNA [ J]. J Biol Chem, 1993,268:23747 - 23750.
  • 9Purcell-Huynh DA,Farese RV, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet [ J ]. J Clin Invest, 1995,95 : 2246 - 2257.
  • 10Ito Y,Azrolan N, O' Connell A, et al. Hypertriglyceridemia as a result of human apoCⅢ gene expression in transgenie mice [ J ]. Science, 1990,249 : 790 - 793.

共引文献20

同被引文献32

  • 1王宇辉,刘国庆.胆固醇和甘油三酯代谢紊乱与代谢性心血管病的研究进展[J].中国医学前沿杂志(电子版),2012,4(8):19-22. 被引量:12
  • 2李国平,陈保生,薛红,曾武威,吴刚.载脂蛋白C3基因多态性-482C>T与血浆脂质的关系[J].中国动脉硬化杂志,2005,13(3):335-339. 被引量:12
  • 3Nicholls SJ, Uno K, Kataoka Y. Clinical experience with rosuvastatin in the management of hyperlipiderniaand the reduction ofeaediovascular risk [ J ]. Expert Rev Cardiovase Ther, 2011,9 ( 11 ) : 1383-1390.
  • 4Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options [ J ]. Nat Med ,2011,17 ( 11 ) : 1410-1422.
  • 5Tibo|la G, Norata GD, Artali R, et al. Proprotein convertase subtilisin / kexin type 9 (PCSK9) :from structure-function relation to therapeutic inhibition[ J]. Nutr Metab Cardiovasc Dis,2011,21 ( 11 ) :835-843.
  • 6Ai D, Chen C, Han S, et al. Regulation of hepatic LDL receptors by MTORC1 and PCSK9 In mice [ J]. J Clin Invest, 2012, 122 (4) :1262-1270.
  • 7Petersen KF, Dufour S, Hariri A, et al. Transcriptional activation of apolipoprotein C3 gene variants in nonalcoholic fatty liver disease [ J ]. N Engl J Med,2010,36 (2) : 1082-1089.
  • 8Zhang X,Qi R,Xian X, et al. Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet [ J]. Circ Res,2008,102 ( 2 ) :250-256.
  • 9Weinstein MM, Yin L, Tu Y, et al. Chylomicronemia elicits athemsclemsis in mice-brief report [ J ]. Arterioseler Thromb Vase Bio1,2010,30( 1 ) :20-23.
  • 10Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function [ J ]. Nat Rev Cardiol, 2009,6 (7) :455 -463.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部